Skip to content
naulon
Not checkedNot checked for notices yet.

Targeting Solid Tumors With BTK Inhibitors

Fatih M. Uckun, Taracad Venkatachalam

Frontiers in Cell and Developmental Biology · 2021

doi:10.3389/fcell.2021.650414 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use of BTK inhibitors may through lead optimization and translational research lead to the development of new and effective combination regimens for metastatic and/or therapy-refractory solid tumor patients.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.